The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.
PLYMOUTH MEETING, Pa., Nov. 19, 2024 /PRNewswire/ -- The Institute for Safe Medication Practices (ISMP) is proud to announce ...
VNS Health Total (HMO D-SNP) has earned five stars from the New York State Department of Health (NYSDOH), and received the highest Quality Incentive rating of any dual-eligible Medicaid Advantage ...
AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...
GlobalData on MSN8h
Roche secures CE mark for ovarian cancer detection testRoche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...
AbbVie says that Elahere is the first and only folate receptor alpha (FRÉ‘)-directed antibody drug conjugate (ADC) medicine ...
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback